Gastric Inhibitory Polypeptide (GIP): What It Does and Why It Matters

Key takeaways

• What GIP is: A 42-amino acid incretin hormone secreted by K-cells in the upper small intestine in response to fat, carbohydrate, and protein ingestion.
• Primary function: Amplifies glucose-stimulated insulin secretion in a glucose-dependent manner; does not cause hypoglycemia at normal blood glucose levels.
• Incretin role: Together with GLP-1, GIP accounts for 25 to 70% of postprandial insulin secretion in healthy individuals, a phenomenon called the incretin effect.
• In type 2 diabetes: GIP's insulinotropic action is markedly blunted, a central pathophysiological feature now called the "incretin defect."
• Therapeutic relevance: As of April 2026, GIP is a co-target of tirzepatide (Mounjaro/Zepbound), an FDA-approved dual GIP/GLP-1 receptor co-agonist that reduced HbA1c and body weight more than semaglutide 1 mg in the SURPASS-2 head-to-head trial.
• Beyond metabolism: GIP receptors are expressed in adipose tissue, bone, cardiovascular tissue, and the brain, and evidence for roles in adipose lipid metabolism, bone turnover, and neuroprotection is accumulating.

Most people encounter the term "GIP" through news coverage of tirzepatide (the dual GIP/GLP-1 receptor agonist marketed as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity), which has shown superior HbA1c and weight outcomes versus semaglutide 1 mg in the SURPASS-2 head-to-head trial. GIP is the "G" in that mechanism: gastric inhibitory polypeptide, now more often called the glucose-dependent insulinotropic polypeptide, whose receptor tirzepatide agonizes alongside GLP-1. Understanding what GIP actually does biologically helps explain why dual targeting produces the observed metabolic outcomes.

What GIP is

GIP is a 42-amino acid polypeptide hormone belonging to the secretin-glucagon superfamily. It is secreted by K-cells (a type of enteroendocrine cell) in the duodenum and proximal jejunum (the upper small intestine) in response to ingestion of dietary fat, carbohydrate, and protein. Both its structure and incretin role are well established, and its discovery and pharmacology have been mapped from cellular origin to therapeutic implications.

Discovery and history

GIP was purified from porcine small intestine in the early 1970s, and a 1971 sequencing effort reported GIP's complete amino acid sequence. The name "gastric inhibitory polypeptide" reflects the initial hypothesis that GIP's primary role was to inhibit gastric acid secretion, a function that proved to be minor. Subsequent characterization in the 1980s and 1990s established that its dominant physiological action is to amplify postprandial insulin secretion in a glucose-dependent manner, prompting researchers to advocate for the alternative name "glucose-dependent insulinotropic polypeptide," which preserves the GIP acronym while more accurately describing its function.

How GIP is made and released

GIP is synthesized by K-cells as a larger prepro-GIP precursor that undergoes proteolytic processing to yield the 42-amino acid active form. K-cells are located primarily in the duodenum and proximal jejunum (the first segment of the small intestine that receives chyme from the stomach), positioning them to detect ingested nutrients rapidly after a meal. The potent secretagogues are glucose, long-chain fatty acids, and large neutral amino acids. After secretion, GIP enters the portal circulation, reaches the pancreas, and binds GIP receptors on beta cells. The active form circulates with a half-life of approximately 5 to 7 minutes before being inactivated by the enzyme dipeptidyl peptidase-IV (DPP-IV), which cleaves the first two amino acids from the N-terminus of GIP to produce GIP(3-42), an inactive truncated form.

GIP receptors and signaling pathway

The GIP receptor is a G protein-coupled receptor that activates adenylyl cyclase, producing cAMP as a second messenger. In pancreatic beta cells, cAMP accumulation via PKA and Epac pathways potentiates the glucose-stimulated insulin-secretion response. This glucose-dependency is physiologically critical: GIP's insulinotropic action is substantially diminished at low glucose concentrations, so it does not promote hypoglycemia in fasted states. That glucose-dependence sits at the center of incretin biological actions.

GIP's role in the incretin effect

The incretin effect, the amplification of insulin secretion observed after oral glucose compared to intravenous glucose, is the physiological context in which GIP's function is most clearly defined. In healthy people, GLP-1 and GIP drive postprandial insulin, and GIP secretion tracks insulin across the day, rising with each meal. In human subjects, both sides of GIP's insulin and glucagon contribution depend on the prevailing blood glucose level.

GIP's bidirectional role in glucose regulation

GLP-1 and GIP both act on glucagon in a glucose-dependent way, but in opposite directions: GLP-1 suppresses glucagon while GIP increases it. In healthy people, GIP stimulates glucagon secretion from alpha cells at fasting and lower glucose levels, a counter-regulatory response, while at hyperglycemia its insulin-releasing effect prevails and the glucagon response is weaker. This alpha-cell glucagon action is what separates GIP pharmacology from GLP-1's, and it shapes how dual GIP/GLP-1 agonists affect glucagon dynamics in clinical practice.

Join 150,000+ others building better health

Get the science behind better health, every week.

SubscribeSigning up...

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

Thanks for signing up!

Check your inbox — your first issue is on the way. We send clinically reviewed health science, never spam.

GIP in type 2 diabetes: the incretin defect

One of the most clinically significant features of type 2 diabetes is that GIP's insulinotropic action is markedly blunted, a shift known as the "incretin defect." The incretin effect is reduced in type 2 diabetes even though GIP itself is still secreted: GIP loses much of its acute insulinotropic activity for reasons that are not fully established. The same incretin loss accompanies obesity, though which condition drives the other remains unclear. The contrast with GLP-1 is the useful part. GIP's insulinotropic response is impaired in diabetes while GLP-1's action is preserved in type 2 diabetes, which is why GLP-1 receptor agonists work as monotherapy and GIP receptor agonism alone was historically seen as inadequate.

How GIPR desensitization may explain the incretin defect

A receptor under constant stimulation stops answering. Chronic desensitization uncouples a G protein-coupled receptor from its signaling cascade, pulls it inside the cell, and turns down how much of it gets made. Circulating GIP is normal or elevated in obesity and diabetes, and in rodent and cultured-cell models, elevated GIP may chronically desensitize the GIP receptor.

Other conditions where GIP signaling is altered

Diabetes and obesity are not the only settings where GIP signaling shifts:

• Food-induced Cushing syndrome: a post-meal rise in GIP can drive cortisol secretion even when ACTH is low.
• Cystic-fibrosis-related diabetes: GIP's insulinotropic effect is attenuated in cystic fibrosis.
• Insulinoma and other neuroendocrine tumors: GIP overproduction and receptor upregulation are reported, yet the insulinotropic effect often disappears.
• Chronic kidney disease: reduced renal clearance raises circulating GIP without identified additional biological effects.

GIP vs. GLP-1: key differences

GIP and GLP-1 are both gut-derived incretin polypeptide hormones, but they differ in cellular origin, receptor distribution, and several key downstream effects. Understanding these differences explains the rationale for dual targeting in tirzepatide.

| Attribute | GIP | GLP-1 | |---|---|---| | Cellular origin | K-cells in duodenum and proximal jejunum (upper small intestine) | L-cells in distal small intestine and colon (lower gut) | | Amino acid count | 42 amino acids | 30 amino acids; circulates as the bioactive GLP-1(7-36) amide form | | Secretion timing and clearance | Secreted within minutes of nutrient ingestion; peaks 30 to 60 minutes after a meal; plasma half-life of 5 to 7 minutes | Also secreted within minutes of nutrient ingestion; inactivated by DPP-4 faster than GIP | | Effect on glucagon | Increases glucagon in a glucose-dependent way; strongest at low glycemia | Suppresses glucagon in a glucose-dependent way (more consistent glucagon suppression) | | Gastric emptying | Does not substantially slow gastric emptying | Slows gastric emptying, contributing to postprandial glucose flattening and early satiety | | Appetite and satiety | Appetite effects seen in animal studies; not confirmed in humans | Significant satiety-promoting effects through hypothalamic GLP-1 receptors | | Adipose tissue effects | Increases postprandial triglyceride storage in white adipose tissue; has local adipokine-modulating effects | Limited direct adipose effects; weight reduction primarily through satiety and energy intake | | Impairment in type 2 diabetes | Severely blunted insulinotropic response (incretin defect) | Relatively preserved; this is why GLP-1 receptor agonists work as monotherapy |

The rationale for tirzepatide's dual GIP/GLP-1 targeting rests on the complementarity of these profiles: GLP-1 drives sustained satiety and gastric-emptying effects; GIP may contribute additional metabolic effects in adipose tissue and bone. Across the SURPASS tirzepatide trials, the completed head-to-head data show HbA1c reductions and weight loss greater than semaglutide 1 mg, supporting the dual-agonist rationale.

GIP's effects beyond insulin secretion

The identification of GIP receptors in tissues beyond the pancreas has expanded understanding of GIP biology substantially over the past decade.

Adipose tissue and fat metabolism

GIP receptors are expressed in adipose tissue, where GIP promotes triglyceride storage in adipose tissue after a meal and modulates lipid metabolism more broadly. Those receptors sit throughout adipose tissue, unlike GLP-1 receptors, though within white fat the receptor localizes mainly to pericytes and mesothelial cells. The genetic evidence is direct: deleting the GIP receptor protects mice from fat accumulation through effects on energy expenditure and adipose lipid metabolism. That adipose arm is why GIP's role beyond insulin matters in obesity-associated metabolic disorders.

GIP, appetite, and the gut-brain axis

GIP receptors are not confined to the gut and pancreas. GIPR expression is distributed through the brain, and in mice, activating hypothalamic GIPR neurons acutely reduces food intake, while GIPR neurons in the dorsal vagal complex appear to influence energy balance. Whether endogenous GIP shapes human appetite is a separate question, and the honest answer is that GIP's role in appetite regulation has not been clearly defined.

Bone metabolism

GIP has anabolic effects on bone that are less widely known than its metabolic roles. GIP receptors are expressed in osteoblasts, and GIP signaling promotes bone formation while inhibiting resorption, effects consistent with the observation that postprandial bone resorption markers decrease after eating, in a pattern that parallels postprandial GIP secretion. In healthy men, blocking the GIP receptor blunts GIP's bone effect, confirming the physiological relevance of GIP-bone signaling. The bone effects of tirzepatide and its GIP receptor component are an active area of investigation as of April 2026.

Cardiovascular and neuroprotective effects

GIP receptors are expressed at low levels in cardiomyocytes and cardiac pericytes, and preclinical evidence suggests GIP signaling may have protective cardiovascular effects. Emerging work on GIP in cardiovascular disease points to a role in vascular biology, and the question extends further to GIP in atherosclerotic disease. The brain shows a parallel pattern: GIP is neuroprotective in animal models, and GIP reduces ferroptosis in mouse brain via Epac/Rap1 signaling pathways. These are preclinical findings; human trial data specifically for GIP's cardiovascular or neuroprotective effects is limited as of April 2026.

Can GIP be measured in blood?

GIP can be measured, though the assay belongs to research rather than routine care. Plasma GIP is measured with commercially available ELISA kits that do not cross-react with GLP-1 or GLP-2, and the assay decides what the number means: antibodies aimed at the N-terminus quantify the active GIP(1-42) form, while C-terminal antibodies measure total GIP secretion. Because DPP-4 keeps converting active GIP into inactive GIP(3-42), collection and handling shape the result.

GIP and tirzepatide: the clinical evidence

The most consequential contemporary application of GIP biology is tirzepatide. Tirzepatide, with its dual receptor mechanism, produced greater metabolic outcomes than semaglutide 1 mg in head-to-head data. Pooled trial evidence on tirzepatide efficacy in diabetes shows superiority over comparators including semaglutide in HbA1c reduction. Across doses, tirzepatide produced 7.7 to 11.8 kg weight reductions versus placebo. The pooled HbA1c reduction data confirm dose-dependent superiority over GLP-1 agonist monotherapy. As of April 2026, tirzepatide is FDA-approved for type 2 diabetes (Mounjaro), chronic weight management (Zepbound), and moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound). The debate about how much of tirzepatide's advantage over GLP-1 monotherapy comes from its GIP receptor component, versus enhanced GLP-1 receptor engagement, remains an active area of research.

Why blocking GIP is studied alongside agonism

Here is the counterintuitive part of GIP pharmacology: sustained agonism at the GIP receptor produces desensitization that starts to resemble blockade, so pushing the receptor in either direction is being explored for fat loss. Obesity is characterized by GIP overexpression and hyperinsulinemia, which is the argument for testing antagonism. A selective GIP receptor antagonist has been infused in healthy volunteers as a physiological research tool, and whether blocking GIP helps in obesity remains undetermined in humans.

What blunted GIP signaling means for metabolic health

GIP's insulinotropic action is markedly blunted in people with type 2 diabetes: GIP is still secreted, but the insulin-secretion response to it is markedly reduced, for reasons that are not fully established. This "incretin defect" is a measurable physiological change that contributes to postprandial glucose dysregulation and represents a meaningful pathophysiological difference between healthy metabolic function and type 2 diabetes. Understanding how fasting glucose, postprandial insulin secretion, and long-term glycemia interact, through the incretin system that GIP and GLP-1 constitute, provides the biological context for interpreting standard metabolic bloodwork.

Fasting insulin, fasting glucose, and HbA1c are the practical clinical markers for this incretin system. Establishing these baselines before and during metabolic health interventions gives the data its interpretive context, a principle at the core of Superpower's approach to preventive health.

Which biomarkers are relevant if you are exploring GIP biology?

Direct GIP measurement is not standard clinical practice. The core metabolic biomarkers do not measure incretin activity directly. What they reflect is the downstream glycemic and lipid result that insulin and incretin signaling help produce.

• Fasting insulin: Reflects baseline insulin secretory function. In the context of GIP biology, fasting insulin is the practical starting point, since GIP's measurable downstream effect runs through insulin secretion. Elevated fasting insulin indicates insulin resistance, a state in which the incretin system is working against a background of impaired insulin action. Fasting insulin is not part of the baseline panel; it is available via the Advanced Blood Panel add-on.
• Fasting glucose: Foundational metabolic baseline. The efficiency of GIP's postprandial insulin amplification affects how well glucose is cleared after meals.
• Hemoglobin A1c (HbA1c): The primary efficacy endpoint across the SURPASS trials. A baseline HbA1c captures three months of cumulative glycemic control, reflecting how well the incretin system, including GIP, is maintaining postprandial glucose homeostasis.
• Triglycerides: GIP directly promotes triglyceride storage in adipose tissue postprandially. Elevated fasting triglycerides reflect dysfunctional lipid metabolism that may involve impaired GIP-adipose signaling alongside hepatic and dietary factors.
• hs-CRP: In the cardiovascular context of GIP biology, high-sensitivity CRP is the standard inflammation marker used alongside lipids to characterize atherosclerotic risk.

These incretin-relevant markers describe blood sugar and insulin sensitivity, the interpretive framework for understanding what these numbers reflect about underlying polypeptide hormone function.

See your metabolic markers with a Superpower panel

No standard blood panel measures GIP, and no Superpower panel measures it either. What you can see is the metabolic system GIP feeds into. The Superpower Blood Panel includes glucose, HbA1c, triglycerides, and high-sensitivity CRP, four of the metabolic and inflammation biomarkers among the 100+ it measures, so you can watch how your body handles fuel over time rather than guessing. Start with Superpower and build a baseline worth tracking.

Measured by FDA-cleared clinical laboratory methods; used to aid clinician evaluation; not a stand-alone diagnosis.

SAFETY AND REGULATORY NOTICE

Tirzepatide (Mounjaro, Zepbound) is a prescription medication. It carries a boxed warning for risk of thyroid C-cell tumors; it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tirzepatide is not recommended during pregnancy. Serious adverse events reported include pancreatitis, gallbladder disease, acute kidney injury, and severe gastrointestinal reactions. Common adverse events include nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, and injection-site reactions.

This article is for general information and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any prescription medication.

Full FDA-approved prescribing information for tirzepatide and other GLP-1/GIP pathway medications is available on DailyMed.